144,800 Shares in Gilead Sciences, Inc. $GILD Acquired by Louisiana State Employees Retirement System

Louisiana State Employees Retirement System bought a new position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) during the first quarter, according to its most recent Form 13F filing with the SEC. The fund bought 144,800 shares of the biopharmaceutical company’s stock, valued at approximately $20,181,000.

Several other large investors have also recently modified their holdings of the business. Vanguard Group Inc. increased its stake in shares of Gilead Sciences by 1.8% in the fourth quarter. Vanguard Group Inc. now owns 121,097,336 shares of the biopharmaceutical company’s stock valued at $14,863,487,000 after buying an additional 2,113,692 shares during the period. State Street Corp boosted its holdings in Gilead Sciences by 1.9% in the fourth quarter. State Street Corp now owns 60,240,518 shares of the biopharmaceutical company’s stock valued at $7,393,921,000 after acquiring an additional 1,151,213 shares during the last quarter. Price T Rowe Associates Inc. MD increased its position in Gilead Sciences by 4.5% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 27,698,660 shares of the biopharmaceutical company’s stock valued at $3,399,734,000 after purchasing an additional 1,195,269 shares during the period. Bank of America Corp DE increased its position in Gilead Sciences by 15.2% during the 4th quarter. Bank of America Corp DE now owns 23,121,620 shares of the biopharmaceutical company’s stock valued at $2,837,948,000 after purchasing an additional 3,046,688 shares during the period. Finally, Norges Bank bought a new position in Gilead Sciences during the 4th quarter worth approximately $2,617,152,000. Institutional investors own 83.67% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently weighed in on the stock. Royal Bank Of Canada reiterated a “sector perform” rating on shares of Gilead Sciences in a research report on Monday, June 8th. Maxim Group raised shares of Gilead Sciences from a “hold” rating to a “buy” rating and set a $165.00 price target on the stock in a research report on Wednesday, May 20th. Weiss Ratings lowered Gilead Sciences from a “buy (b)” rating to a “buy (b-)” rating in a research report on Thursday, May 28th. The Goldman Sachs Group boosted their price objective on Gilead Sciences from $125.00 to $130.00 and gave the company a “neutral” rating in a research note on Friday, April 17th. Finally, Truist Financial restated a “buy” rating and set a $157.00 target price (up from $155.00) on shares of Gilead Sciences in a research report on Friday, May 8th. Twenty-five research analysts have rated the stock with a Buy rating and four have given a Hold rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $158.41.

Gilead Sciences Trading Down 1.1%

GILD opened at $123.84 on Friday. The company has a fifty day moving average price of $130.42 and a two-hundred day moving average price of $134.33. Gilead Sciences, Inc. has a 1-year low of $105.79 and a 1-year high of $157.29. The company has a market cap of $153.76 billion, a P/E ratio of 16.87 and a beta of 0.31. The company has a current ratio of 1.97, a quick ratio of 1.77 and a debt-to-equity ratio of 0.89.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings data on Thursday, May 7th. The biopharmaceutical company reported $2.03 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.91 by $0.12. The company had revenue of $6.96 billion for the quarter, compared to analysts’ expectations of $6.91 billion. Gilead Sciences had a net margin of 30.99% and a return on equity of 48.19%. The business’s revenue was up 4.4% on a year-over-year basis. During the same quarter in the prior year, the firm earned $1.81 EPS. Gilead Sciences has set its FY 2026 guidance at -1.050–0.650 EPS. Analysts predict that Gilead Sciences, Inc. will post -0.8 EPS for the current fiscal year.

Gilead Sciences Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Monday, June 29th. Investors of record on Monday, June 15th will be given a $0.82 dividend. The ex-dividend date of this dividend is Monday, June 15th. This represents a $3.28 annualized dividend and a yield of 2.6%. Gilead Sciences’s dividend payout ratio (DPR) is presently 44.69%.

Gilead Sciences News Roundup

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: The U.S. FDA approved Trodelvy for first-line treatment of metastatic triple-negative breast cancer, expanding the drug’s addressable market and strengthening Gilead’s oncology growth story. U.S. FDA Approves Trodelvy for First-Line Treatment of Metastatic Triple-Negative Breast Cancer
• Positive Sentiment: Merck also received FDA approval for KEYTRUDA combinations that include Trodelvy, which could increase Trodelvy’s use in combination regimens and support broader adoption. FDA Approves KEYTRUDA combinations with Trodelvy
• Positive Sentiment: Gilead also received European Commission approval to expand Trodelvy’s label in metastatic TNBC, further widening the drug’s commercial opportunity outside the U.S. Gilead Wins EC Approval to Expand Trodelvy’s Label in Metastatic TNBC
• Neutral Sentiment: Short-interest data showed no meaningful change, so it does not appear to be a major driver of the stock’s move.
• Negative Sentiment: Despite the Trodelvy approvals, Gilead’s shares still dipped versus the broader market, suggesting investors may be taking profits or focusing on broader market weakness rather than the regulatory upside. Gilead Sciences Dips More Than Broader Market: What You Should Know

Insider Buying and Selling at Gilead Sciences

In related news, insider Johanna Mercier sold 28,000 shares of Gilead Sciences stock in a transaction that occurred on Friday, May 15th. The stock was sold at an average price of $131.29, for a total transaction of $3,676,120.00. Following the transaction, the insider owned 125,779 shares of the company’s stock, valued at $16,513,524.91. The trade was a 18.21% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Daniel Patrick O’day sold 15,000 shares of the company’s stock in a transaction on Monday, June 1st. The stock was sold at an average price of $131.46, for a total value of $1,971,900.00. Following the sale, the chief executive officer owned 617,567 shares of the company’s stock, valued at $81,185,357.82. This trade represents a 2.37% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders sold 68,000 shares of company stock worth $8,930,150. Insiders own 0.30% of the company’s stock.

Gilead Sciences Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.